Sign in
4

Changes in Ownership

CytomX Therapeutics, Inc. Filed Acc 0001140361-17-011297

Chief Financial Officer acquired 2,500 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Goeltz II Robert C. · Chief Financial Officer

Table I: Non-derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2017-03-09 Exercise or conversion : show line 1 in the form +2,500 $4.47 $11,182 9,789 D

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2017-03-09 Exercise or conversion : show line 2 in the form Stock Option (right to buy) −2,500 239,175 D
Loading xslF345X03/doc1.xml…